Literature summary for 2.7.1.36 extracted from

van der hilst, J.C.H.; Kluve-Beckerman, B.; Bodar, E.J.; van der Meer, J.W.M.; Drenth, J.P.H.; Simon, A.
Lovastatin inhibits formation of AA amyloid (2008), J. Leukocyte Biol., 83, 1295-1299.

Search for more literature for 2.7.1.36

Application

Application	Comment	Organism
medicine	inhibition of the isoprenoid pathway results in a dose-dependent reduction of amyloid formed. The inhibitory effects of lovastatin are reversible by addition of farnesol but not geranylgeraniol. Farnesyl transferase inhibition also inhibits amyloidogenesis	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
lovastatin	inhibition of isoprenoid pathway, resulting in a dose-dependent reduction of amyloid formed compared with mononuclear cells that are exposed only to serum amyloid. The inhibitory effects of lovastatin are reversible by addition of farnesol but not geranylgeraniol. Farnesyl transferase inhibition also inhibits amyloidogenesis	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
monocyte	-	Homo sapiens	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)